{"entity":{"id":"dan-222","kind":"drug","name":"DAN-222","aka":[],"tldr":"DAN-222 is an experimental high-capacity drug conjugate from Dantari, in phase 2 trials for HER2-negative metastatic breast cancer; its current status is not stated.","summary":"DAN-222 is a high-capacity drug conjugate (polymer-based) from Dantari. A high-capacity drug conjugate carrying a topoisomerase 1 inhibitor payload. Its furthest stage is phase 2, for HER2-negative metastatic breast cancer. ClinicalTrials.gov registers it in 2 studies linked below. Own phase 1 NCT05261269 completed; the I-SPY phase 2 platform arm 'Dan222 + Niraparib' is closed. Company status not verified (domain parked). Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Dantari: biospace.com","url":"https://www.biospace.com/dantari-launches-with-47m-to-make-better-adcs"},{"label":"Dantari: biopharmadive.com","url":"https://www.biopharmadive.com/news/dantari-launch-cancer-drug-conjugates/638266/"},{"label":"Dantari: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05261269"},{"label":"Dantari: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT01042379"},{"label":"ClinicalTrials.gov: trials of DAN-222","url":"https://clinicaltrials.gov/search?intr=DAN-222"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["dantari"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05261269","i-spy-2-2"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"DAN-222","modality":"High-capacity drug conjugate (polymer-based)","mechanism":"A high-capacity drug conjugate carrying a topoisomerase 1 inhibitor payload.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/dan-222/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"company":[{"id":"dantari","kind":"company","name":"Dantari","route":"/companies/dantari/"}],"trial":[{"id":"nct05261269","kind":"trial","name":"A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer","route":"/trials/nct05261269/"},{"id":"i-spy-2-2","kind":"trial","name":"I-SPY 2.2","route":"/trials/i-spy-2-2/"}]}}